BioHarvest Sciences (NASDAQ:BHST) Posts Earnings Results, Beats Expectations By $0.01 EPS

BioHarvest Sciences (NASDAQ:BHST) issued its quarterly earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01, FiscalAI reports. The business had revenue of $7.87 million during the quarter, compared to analyst estimates of $9.31 million. BioHarvest Sciences had a negative net margin of 31.21% and a negative return on equity of 58.30%.

BioHarvest Sciences Trading Down 3.9%

NASDAQ BHST traded down $0.07 during trading hours on Thursday, reaching $1.68. The company’s stock had a trading volume of 97,403 shares, compared to its average volume of 35,231. The business has a 50-day simple moving average of $1.65 and a 200 day simple moving average of $3.11. BioHarvest Sciences has a 52 week low of $1.37 and a 52 week high of $8.30. The stock has a market cap of $32.97 million, a PE ratio of -3.23 and a beta of 0.93.

Wall Street Analyst Weigh In

BHST has been the topic of several research analyst reports. Roth Capital reduced their price target on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, September 14th. Finally, Maxim Group cut their price objective on BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $6.50.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.